These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 11857416)

  • 21. Screening for hepatocellular carcinoma in patients with advanced cirrhosis.
    Chalasani N; Horlander JC; Said A; Hoen H; Kopecky KK; Stockberger SM; Manam R; Kwo PY; Lumeng L
    Am J Gastroenterol; 1999 Oct; 94(10):2988-93. PubMed ID: 10520857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan.
    Yu MW; Chang HC; Chen PJ; Liu CJ; Liaw YF; Lin SM; Lee SD; Lin SC; Lin CL; Chen CJ
    Int J Epidemiol; 2002 Oct; 31(5):1008-15. PubMed ID: 12435776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis.
    Tanaka K; Sakai H; Hashizume M; Hirohata T
    Jpn J Cancer Res; 1998 Dec; 89(12):1241-50. PubMed ID: 10081484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
    Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
    BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B.
    Wun YT; Dickinson JA
    Cochrane Database Syst Rev; 2003; (2):CD002799. PubMed ID: 12804438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development.
    Benvegnù L; Noventa F; Bernardinello E; Pontisso P; Gatta A; Alberti A
    Gut; 2001 Jan; 48(1):110-5. PubMed ID: 11115831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
    Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
    J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.
    Bolondi L; Sofia S; Siringo S; Gaiani S; Casali A; Zironi G; Piscaglia F; Gramantieri L; Zanetti M; Sherman M
    Gut; 2001 Feb; 48(2):251-9. PubMed ID: 11156649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors.
    Fasani P; Sangiovanni A; De Fazio C; Borzio M; Bruno S; Ronchi G; Del Ninno E; Colombo M
    Hepatology; 1999 Jun; 29(6):1704-7. PubMed ID: 10347111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India.
    Kumar M; Kumar R; Hissar SS; Saraswat MK; Sharma BC; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2007 Jul; 22(7):1104-11. PubMed ID: 17559381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
    Lu SN; Wang JH; Liu SL; Hung CH; Chen CH; Tung HD; Chen TM; Huang WS; Lee CM; Chen CC; Changchien CS
    Cancer; 2006 Nov; 107(9):2212-22. PubMed ID: 17019738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum alpha-fetoprotein may have a significant role in the surveillance of hepatocellular carcinoma in hepatitis B endemic areas.
    Sinn DH; Yi J; Choi MS; Kim YJ; Gwak GY; Lee JH; Koh KC; Paik SW; Yoo BC
    Hepatogastroenterology; 2015; 62(138):327-32. PubMed ID: 25916058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.
    Fattovich G; Pantalena M; Zagni I; Realdi G; Schalm SW; Christensen E;
    Am J Gastroenterol; 2002 Nov; 97(11):2886-95. PubMed ID: 12425564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers.
    Yu MW; Hsu FC; Sheen IS; Chu CM; Lin DY; Chen CJ; Liaw YF
    Am J Epidemiol; 1997 Jun; 145(11):1039-47. PubMed ID: 9169913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey.
    Chalasani N; Said A; Ness R; Hoen H; Lumeng L
    Am J Gastroenterol; 1999 Aug; 94(8):2224-9. PubMed ID: 10445554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis.
    Worland T; Harrison B; Delmenico L; Dowling D
    J Gastrointest Cancer; 2018 Dec; 49(4):476-480. PubMed ID: 28920172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.
    Reddy KR; McLerran D; Marsh T; Parikh N; Roberts LR; Schwartz M; Nguyen MH; Befeler A; Page-Lester S; Tang R; Srivastava S; Rinaudo JA; Feng Z; Marrero JA
    Gastroenterology; 2023 Oct; 165(4):1053-1063.e6. PubMed ID: 37429366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study.
    Hallager S; Ladelund S; Kjaer M; Madsen LG; Belard E; Laursen AL; Gerstoft J; Røge BT; Grønbaek KE; Krarup HB; Christensen PB; Weis N
    J Viral Hepat; 2018 Jan; 25(1):47-55. PubMed ID: 28750141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.
    Cho HJ; Kim B; Lee JD; Kang DR; Kim JK; Lee JH; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim SS; Cheong JY; Cho SW
    Am J Gastroenterol; 2017 Mar; 112(3):460-470. PubMed ID: 27779194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.